Related Experiment Video

Updated: Jul 16, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor

Robert Roskoski1

  • 1Blue Ridge Institute for Medical Research, Horse Shoe, NC 28742, USA. rrj@brimr.org

Biochemical and Biophysical Research Communications
|March 21, 2007
PubMed

Insights

Sunitinib is a targeted therapy drug that inhibits multiple receptor tyrosine kinases, including VEGFRs and PDGFRs, crucial for tumor growth and blood vessel formation. It is approved for treating advanced renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumors.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Sunitinib targets multiple receptor protein-tyrosine kinases, including vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs).
  • VEGFRs and PDGFRs are critical for angiogenesis and vascular stability, processes vital for tumor growth and metastasis.
  • Activating mutations in Kit and PDGFRalpha are implicated in gastrointestinal stromal tumors (GISTs).

Purpose of the Study:

  • To elucidate the kinase inhibition profile of sunitinib.
  • To explain the mechanism of action of sunitinib in inhibiting angiogenesis.
  • To highlight the therapeutic applications of sunitinib in specific cancer types.

Main Methods:

  • In vitro kinase assays to determine sunitinib's inhibitory activity against various receptor tyrosine kinases.
  • Assessment of sunitinib's effects on angiogenesis-related signaling pathways.
  • Review of clinical approvals and mechanisms for sunitinib in renal cell carcinoma and GIST.

Main Results:

  • Sunitinib inhibits at least eight receptor protein-tyrosine kinases, including VEGFRs, PDGFRs, Kit, Flt-3, and CSF-1R.
  • Sunitinib effectively inhibits angiogenesis by diminishing signaling through VEGFR1, VEGFR2, and PDGFRbeta.
  • Sunitinib is approved for metastatic renal cell carcinoma and imatinib-resistant GISTs with specific mutations.

Conclusions:

  • Sunitinib is a potent multi-targeted tyrosine kinase inhibitor with significant anti-angiogenic properties.
  • Its efficacy in renal cell carcinoma and GISTs is attributed to its inhibition of key signaling pathways involved in tumor vascularization and growth.
  • Sunitinib represents an important therapeutic option for patients with advanced or resistant cancers.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...